España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Axsome Therapeutics
AXSM
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$137.75
8.65
6.70%
At close: -
$138.95
1.20
0.87%
After Hours: 6:21 PM EDT
Get Report
Comment
Q4 2024 Earnings were released on Tue Feb 18th, before the market open
The most recent conference call was at 8:00 AM, 3 days ago
Click to view past webcast
Axsome Therapeutics (AXSM) Forecast
News
Earnings
Axsome Therapeutics (AXSM) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Axsome Therapeutics (NASDAQ:AXSM) Stock
Axsome Therapeutics Stock (NASDAQ: AXSM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, February 20, 2025
HC Wainwright & Co. Maintains Buy on Axsome T...
Benzinga Newsdesk
Wednesday, February 19, 2025
Truist Securities Maintains Buy on Axsome The...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Needham Maintains Buy on Axsome Therapeutics,...
Benzinga Newsdesk
Tuesday, February 18, 2025
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?
Erica Kollmann
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Vandana Singh
Axsome Therapeutics Q4 2024 GAAP EPS $(1.54) ...
Benzinga Newsdesk
Earnings Scheduled For February 18, 2025
Benzinga Insights
Sunday, February 16, 2025
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Lekha Gupta
Wednesday, February 12, 2025
Wells Fargo Maintains Overweight on Axsome Th...
Benzinga Newsdesk
Tuesday, February 11, 2025
Deutsche Bank Initiates Coverage On Axsome Th...
Benzinga Newsdesk
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
B of A Securities Maintains Buy on Axsome The...
Benzinga Newsdesk
Mizuho Maintains Outperform on Axsome Therape...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Monday, February 10, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock
Benzinga Insights
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Vandana Singh
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
Axsome Therapeutics Entered Into A Settlement...
Benzinga Newsdesk
Monday, February 03, 2025
Mizuho Maintains Outperform on Axsome Therape...
Benzinga Newsdesk
Truist Securities Maintains Buy on Axsome The...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Friday, January 31, 2025
HC Wainwright & Co. Maintains Buy on Axsome T...
Benzinga Newsdesk
Thursday, January 30, 2025
Axsome Therapeutics Announces FDA Approval Of...
Benzinga Newsdesk
Wednesday, January 29, 2025
RBC Capital Maintains Outperform on Axsome Th...
Benzinga Newsdesk
Tuesday, January 21, 2025
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
12 Analysts Have This To Say About Axsome Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Monday, January 13, 2025
Axsome Therapeutics shares are trading higher...
Benzinga Newsdesk
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Truist Securities Maintains Buy on Axsome The...
Benzinga Newsdesk
Axsome Therapeutics Announced Preliminary Net...
Benzinga Newsdesk
Monday, January 06, 2025
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Tuesday, December 31, 2024
Mizuho Maintains Outperform on Axsome Therape...
Benzinga Newsdesk
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Vandana Singh
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Monday, December 30, 2024
Smart Money Is Betting Big In AXSM Options
Benzinga Insights
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Benzinga Insights
Needham Reiterates Buy on Axsome Therapeutics...
Benzinga Newsdesk
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
Axsome Completes Phase 3 Trials for AXS-05 in...
Benzinga Newsdesk
Thursday, December 12, 2024
Cantor Fitzgerald Reiterates Overweight on Ax...
Benzinga Newsdesk
Wednesday, November 27, 2024
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Vandana Singh
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Tuesday, November 26, 2024
Axsome Therapeutics Reveals AXS-12 Meets Prim...
Benzinga Newsdesk
Monday, November 25, 2024
HC Wainwright & Co. Reiterates Buy on Axsome ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch